Your browser doesn't support javascript.
loading
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
de Wit, Ronald; Vaughn, David J; Fradet, Yves; Fong, Lawrence; Climent, Miguel A; Necchi, Andrea; Petrylak, Daniel P; Gerritsen, Winald R; Gurney, Howard; Quinn, David I; Culine, Stéphane; Sternberg, Cora N; Bajorin, Dean F; Choueiri, Toni K; Xu, Jin; Imai, Kentaro; Homet Moreno, Blanca; Bellmunt, Joaquim; Lee, Jae-Lyun.
Affiliation
  • de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: r.dewit@erasmusmc.nl.
  • Vaughn DJ; Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Fradet Y; Department of Surgery/Urology, CHU de Québec-Université Laval Research Center, Quebec, QC, Canada.
  • Fong L; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Climent MA; Department of Medical Oncology, Valencian Institute of Oncology (IVO Foundation), Valencia, Spain.
  • Necchi A; Department of Medical Oncology, Vita-Salute San Raffaele University and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Petrylak DP; Department of Internal Medicine/Medical Oncology, Smilow Cancer Hospital, Yale New Haven Health, New Haven, CT, USA.
  • Gerritsen WR; Department of Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Gurney H; Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia.
  • Quinn DI; Developmental Therapeutics Program, USC Norris Comprehensive Cancer Center and Division of Cancer Medicine and Blood Diseases, Keck Medicine of USC, Los Angeles, CA, USA.
  • Culine S; Department of Medical Oncology, Saint-Louis Hospital, Paris, France.
  • Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian, New York, NY, USA.
  • Bajorin DF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Choueiri TK; Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Xu J; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA.
  • Imai K; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA.
  • Homet Moreno B; Department of Medical Oncology, Merck & Co. Inc, Rahway, NJ, USA.
  • Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute and IMIM Research Institute, Harvard Medical School, Boston, MA, USA.
  • Lee JL; Division of Oncology, Department of Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea.
Eur Urol ; 2024 Aug 21.
Article in En | MEDLINE | ID: mdl-39174409
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Year: 2024 Document type: Article Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Year: 2024 Document type: Article Country of publication: Switzerland